Develops non-viral genetic medicines, led by a bladder-instillable therapy for bladder cancer patients, and is exploring treatments for other cancers and diseases.
10-K for FY2025, filed Dec 22, 2025
Its lead medicine is being developed for patients with bladder cancer whose disease has not responded to BCG treatment; the company plans to sell it itself in the United States if approved and may partner outside the United States.
10-K for FY2025, filed Dec 22, 2025
10-Q for Q3 FY2026, filed Sep 8, 2026
−$32.5MView ↗
8-K, filed Nov 12, 2026
On November 11, 2026, the Company announced results from the pivotal Cohort 1 of its ongoing, Phase 2 LEGEND trial of detalimogene, and…View ↗
8-K, filed Jul 16, 2026
On July 15, 2026, Dr. Richard Glickman resigned as a director and chairman of the Board of Directors (the “Board”) of enGene Therapeutics…View ↗
8-K, filed Jun 15, 2026
On June 15, 2026, the Company announced the implementation of a plan to reduce its workforce by approximately 50% to streamline operations…View ↗
Loading...